AzTrials
AzTrials

Acute DyspneaDREAMNCT07132268

Diaphragm Response in Elderly for Acute Monitoring

An observational study of Acute Dyspnea and Acute Respiratory Failure, run by Centre Hospitalier de Bethune at 9 sites in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Acute dyspnea is a common cause of emergency department admissions among elderly patients. Acute respiratory failure is often multifactorial and requires rapid and reliable evaluation. Read more about this study

Who is it for?
Ages 75 years and older
How many people
145 participants
Where
9 sitesFrance
Study dates
Oct 2026to Oct 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 75 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Study population: Patients Aged 75 and Over Admitted to the Emergency Department for Acute Dyspnea

Who may be able to join

  • Patients aged ≥ 75 years
  • Emergency admission for acute dyspnea
  • Requiring an emergency ultrsoung.
  • Needing to have blood gas levels checked
  • no inclusion Criteria:
  • Acute respiratory distress requiring immediate invasive or non-invasive ventilation
Show all 18Show fewer
  • Respiratory rate ≥ 25 breaths/min, and/or SpO2 ≤ 90%, and/or PaO2 ≤ 60 mmHg, measured at admission on room air or receiving oxygen therapy at ≤ 3L/min.
  • Known diaphragmatic paralysis
  • Patients with degenerative neuromuscular disease
  • State of shock: systolic blood pressure < 90 mmHg and/or mean arterial pressure < 65 mmHg and/or presence of skin mottling and/or CTR > 3s
  • Oxygen requirement ≥ 4 L/min
  • Arterial lactate levels > 2 mmol/L
  • Hypercapnic respiratory acidosis (pH < 7.38 and PaCO2 > 45 mmHg)
  • Dyspnea due to metabolic acidosis (e.g., diabetic ketoacidosis, renal failure)
  • Dyspnea of traumatic origin
  • Refusal to participate or inability to provide informed consent
  • Patients deprived of liberty
  • Patients under guardianship or curatorship

Who cannot join

None listed.

Trial locations and contacts

9 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Alain-Eric DUBART, Doctor contact

03.21.64.42.81

adubart@ch-bethune.fr

9 sites in 1 country

France9 sites
  • Centre Hospitalier Victor Dupouy

    Argenteuil, 95100

    Catherine LE GALL, MD

  • Centre Hospitalier de Béthune

    Béthune, 62408

    Mélanie VERLAY, 0602013068, mverlay@ch-lens.fr

    adubart@ch-bethune.fr

  • Centre Hospitalier de Douai

    Douai, 59507

    Olivier HEMAR, MD

  • Centre Hospitalier Emile Roux

    Le Puy-en-Velay, 43000

    KWAKYE AGYEMANG Angelo Giordano, MD

  • Centre Hospitalier Sud Ile-de-France

    Melun, 77000

    Morsi ELLOUZ, MD

  • Centre Hospitalier de Roubaix

    Roubaix, 59100

    Perrine LIBERT, MD

  • Centre Hospitalier de Saint-Lô

    Saint-Lô, 50000

    Félix AMIOT, MD

  • Centre Hospitalier de Tourcoing

    Tourcoing, 59208

    Florent HENIN, MD

  • Centre Hospitalier de Valenciennes

    Valenciennes, 59300

    Alexandre ANDRIES, MD

Other trials in France

About this study

Official title: Using Diaphragmatic Ultrasound to Predict Acute Respiratory Distress (ARD) in Patients Aged 75 and Over Admitted to the Emergency Department for Acute Dyspnea : Prospective Multicenter Study.

Acute dyspnea is a common cause of emergency department admissions among elderly patients. Acute respiratory failure is often multifactorial and requires rapid and reliable evaluation. Currently, management relies on clinical, biological, and radiological assessments, but diaphragmatic ultrasound could provide an additional tool for real-time respiratory function evaluation. This study aims to integrate this non-invasive technology into the initial assessment of patients to improve care pathways. Hypothesis : Diaphragmatic ultrasound enables reliable assessment of respiratory function and can predict the need for mechanical ventilation.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Occurrence of a severe acute respiratory event within 7 days of admission

    • Placement on invasive mechanical ventilation (intubation) or non invasive ventilation (NIV, high-flow oxygen therapy),
    • Respiratory death, confirmed by an independent adjudication committee blinded to the ultrasound results.

    Explanatory variable: The presence of impaired diaphragmatic function at admission will be defined by:

    • a Tdi (tele-inspiratory thickness) <10%, and/or
    • a diaphragmatic excursion <10 mm.

    Measured: WITHIN 7 DAYS OF ADMISSION

Secondary outcomes (2)
  1. Measurement of diaphragmatic excursion AND Etiology of acute dyspnea

    To study the association between diaphragmatic excursion curve parameters (EDR, inspiratory time, expiratory time, etc.) and the etiology of acute dyspnea in patients aged 75 years and older admitted for acute dyspnea

    Measured: within 7 days

  2. To evaluate the contribution of diaphragmatic ultrasound to the NEWS2 score performed on admission in predicting the occurrence of acute respiratory distress within 7 days.

    The discriminatory power of the NEWS2 score in predicting the occurrence of acute respiratory distress, the discriminatory power of the NEWS2 score combined with impaired diaphragmatic function on admission ultrasound.

    NEWS 2 : The higher the score, the greater the risk of clinical deterioration. 0-4 : low risk Score of 3 in any individual parameter : low-medium 5-6 : moderate risk

    > or = 7 : high risk

    Measured: within 7 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Aug 2025
  2. Study startOct 2026 (estimated)
  3. Primary completionOct 2028 (estimated)
  4. Study completionOct 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
145 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07132268
Sponsor's protocol ID
2025-01
Other IDs
ID-RCB
Acronym
DREAM
Status last verified
Oct 2026
First submitted
3 Jul 2025
Last updated
26 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Dyspnea and Acute Respiratory Failure, run by Centre Hospitalier de Bethune at 9 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 18 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 9 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Alain-Eric DUBART, Doctor (03.21.64.42.81, adubart@ch-bethune.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Occurrence of a severe acute respiratory event within 7 days of admission (time frame: WITHIN 7 DAYS OF ADMISSION). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in